DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVTFree Report) in a research note published on Tuesday morning. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright reduced their price objective on shares of DBV Technologies from $10.00 to $5.00 and set a buy rating for the company in a research report on Wednesday, May 8th.

Get Our Latest Research Report on DBV Technologies

DBV Technologies Stock Up 8.7 %

Shares of NASDAQ:DBVT opened at $0.59 on Tuesday. The business’s 50 day moving average is $0.73 and its 200 day moving average is $0.83. DBV Technologies has a 12-month low of $0.42 and a 12-month high of $2.37. The stock has a market cap of $113.18 million, a price-to-earnings ratio of -1.43 and a beta of 0.73.

DBV Technologies (NASDAQ:DBVTGet Free Report) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. The firm had revenue of $8.88 million for the quarter, compared to the consensus estimate of $1.10 million. During the same period in the previous year, the firm earned ($0.23) EPS. As a group, equities research analysts expect that DBV Technologies will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On DBV Technologies

Several large investors have recently made changes to their positions in the business. Landscape Capital Management L.L.C. purchased a new position in shares of DBV Technologies in the 3rd quarter worth about $94,000. Optiver Holding B.V. increased its holdings in DBV Technologies by 595.2% during the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after buying an additional 235,337 shares during the last quarter. Finally, Cowen AND Company LLC bought a new stake in DBV Technologies in the fourth quarter worth about $49,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Recommended Stories

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.